One-shot wonder? new drug aims to stop liver cancer recurrence
NCT ID NCT06526338
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 30 times
Summary
This study tests a single injection of IP-001 given right after liver cancer treatment (surgery or heat ablation) to see if it can keep the cancer from returning. It involves 126 adults with hepatocellular carcinoma at high risk of recurrence. Participants are followed with regular scans for at least two years to check if the cancer comes back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Louisville
RECRUITINGLouisville, Kentucky, 40202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.